A blood and tissue test for liver cancer
Part of Cancer, Digestive system clinical trials.
This study is looking at a new way to find liver cancer by testing blood and tissue samples. It compares people with liver cancer to people with liver scarring (cirrhosis) but no cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have either a diagnosis of liver cancer (HCC) or liver cirrhosis (scarring of the liver).
- You must be willing and able to sign a consent form.
- You need to have a blood sample and a small amount of liver tissue available that were collected around the same time.
- You cannot have any other active cancer.
- You cannot have had a liver transplant in the past.
- You cannot have had chemotherapy or antiviral medication in the last 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new blood test to help detect liver cancer (HCC) or confirm it’s not present in people with cirrhosis who are being monitored. It may help improve how doctors screen for liver cancer and decide who needs further imaging or treatment.
This study is looking for people with or without liver cancer to test a new way to find liver cancer early using blood or tissue samples. It aims to help catch the disease sooner.
This trial studies a new blood test that looks for DNA from cancer cells' mitochondria to see if it can catch liver cancer coming back earlier. The goal is to help doctors find recurrence faster and improve follow-up care.
This study checks whether a blood test (circulating tumor DNA) can help predict if hepatocellular carcinoma (HCC) will return after curative treatment like surgery or ablation. If it works, it may help doctors plan closer follow-up or earlier treatment if recurrence risk is higher.
This study looks at how well doctors can detect small, early liver cancer and then follow how it changes over time. It may help your care team choose the best next steps based on earlier, clearer detection.
This study uses a simple blood test to monitor tiny pieces of tumor DNA (ctDNA) in people with colorectal cancer that spread to the liver or with liver cancer (HCC), before and after liver surgery or transplant. It aims to help doctors detect cancer return earlier and guide treatment.
Hear when a new Hepato Cellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.